Hetty Carraway, MD
Results of a deep sequencing analysis demonstrated that mutations in 8 high-risk genes are associated with an acute myeloid leukemia (AML) diagnosis. These findings, explained Hetty Carraway, MD, lay the ground work for early detection studies and novel treatment strategies.
on Hematologic Malignancies, Carraway highlighted ongoing genomic research in AML, as well as recent therapeutic advances in the field.
OncLive: What is the prevalence of actionable mutations in AML?
: Things that are really important to remember in the treatment of patients with AML is to think about doing mutation testing by next-generation sequencing for patients at the time of diagnosis, as well as at the time of relapse. These types of mutations can inform how patients will do in terms of prognosis, and it can also inform choice and selection of therapies for them.
Another thing to remember is that as we get novel therapies, know that clinical trials are going to be very important in order to better understand how to combine these [treatments], how to optimize response, and to be mindful of the toxicities that may happen as a result of combination therapy.
In your presentation, you highlighted research about mutations that can predict AML before it is actually diagnosed. Could you discuss that?
There has been some fascinating work on the presence of mutations in patients who do not have a hematologic malignancy—to understand the presence of mutations and clonal hematopoiesis of indeterminate potential. [They looked at the] patients that evolve from having these particular mutations that then go on to have dysplasia, that then go onto have clonal events, that then lead to myelodysplastic syndrome (MDS).
... to read the full story